Viritis Ltd is developing a next-generation, AI-driven antiviral platform designed to rapidly generate targeted therapies against a broad range of viruses and all strains within a given viral family. Viritis combines proprietary algorithms with a patented molecular backbone. The platform enables precise binding to viral genetic material, activating the cell’s innate defense mechanisms to selectively degrade the virus without harming host cells. In addition, novel formulation has been developed for intranasal and systematic administration. Scientific validation has demonstrated 97.1% viral inhibition across five human cell lines, and the molecule ability to naturally disintegrate within hours after completing its function, leaving no harmful residues.

Beyond molecular precision, Viritis integrates a continuous AI–wet lab feedback loop that accelerates the drug development process from design to optimization. The molecule remains stable at elevated temperatures, eliminating the need for cold-chain logistics and reducing cost and operational complexity. With early interest from major pharma players and a regulatory strategy that leverages accelerated pathway following initial approval, Viritis combines strong preclinical traction, scalable platform architecture, and a clear path toward accelerated clinical translation.